Healthcare / Medical Instruments & SuppliesTokyo
$1701.00
-52.00 (-2.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $347.0M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$167.6B
P/E
29.9x
↑EV/EBITDA
15.6x
↑ROE
8.7%
↑Gross Margin
64.5%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.6%
FCF CAGR
-57.8%
FCF margin
1.2%
FCF / Net income
0.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $29.97B · net income $4.64B · FCF $347.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $29.97B | $29.97B | $28.51B | $24.49B | $20.42B |
| Net Income | $4.64B | $4.64B | $6.29B | $5.95B | $5.29B |
| EBITDA | $9.56B | $9.56B | $10.70B | $9.94B | $9.17B |
| EPS | 52.46 | 52.46 | 63.82 | 60.46 | 53.75 |
| Gross Margin | 64.5% | 64.5% | 62.8% | 63.0% | 61.6% |
| Operating Margin | 27.3% | 27.3% | 29.4% | 29.6% | 30.2% |
| Net Margin | 15.5% | 15.5% | 22.0% | 24.3% | 25.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 8.57 | 8.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $347.0M | $347.0M | $129.0M | $4.31B | $4.62B |
| Returns | |||||
| ROE | 8.7% | 8.7% | 12.0% | 11.9% | 11.6% |
| Valuation | |||||
| P/E | 29.95 | 29.95 | 29.22 | 30.71 | 31.29 |
| EV/EBITDA | 15.60 | 15.60 | 15.15 | 15.85 | 15.59 |
| P/B | 3.13 | 3.13 | 3.51 | 3.67 | 3.65 |
| Growth & Yield | |||||
| Revenue Growth | 5.1% | 5.1% | 16.4% | 19.9% | — |
| EPS Growth | -17.8% | -17.8% | 5.6% | 12.5% | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
42.2%
EPS terminal req.
$150.94
Spread vs growth
-60.0%
5Y implied EPS CAGR
28.3%
EPS terminal req.
$182.63
Spread vs growth
-46.1%
10Y implied EPS CAGR
18.8%
EPS terminal req.
$294.13
Spread vs growth
-36.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+43.6%
Start / end P/E
18.9x → 32.4x
EPS bridge
63.82 → 52.46
Residual
-12.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.